Table 1 Baseline characteristics of the linked sample of trial participants as collected in the CHHiP trial. The linked sample is representative of the overall trial population [28]. P-values are calculated using independent sample t-test, Mann–Whitney or chi-squared tests. IQR, interquartile range
|  | CHHiP unlinked sample n = 3110 | Linked sample N = 106 | P-value |
|---|---|---|---|
Age at randomisation to CHHiP (years) | |||
 Median (IQR) | 69 (64–73) | 70 (65–74) | 0.13 |
 Range | 48–85 | 44–82 |  |
Randomisation, n (%) | Â | Â | 0.04 |
 Group 1 (standard schedule, 74Gy/37f) | 1041 (33) | 24 (23) |  |
 Group 2 (hypofractionated schedule 1, 60Gy/20f) | 1029 (33) | 45 (42) |  |
 Group 3 (hypofractionated schedule 2, 57Gy/19f) | 1040 (33) | 37 (35) |  |
Clinical T stage, n (%) | Â | Â | 0.10 |
 T1 | 1125 (36) | 45 (42) |  |
 T2 | 1718 (55) | 48 (45) |  |
 T3 | 264 (9) | 13 (12) |  |
 Missing or unknown | 3 (< 1) | 0 (0) |  |
Type of androgen deprivation therapy, n (%) | Â | Â | 0.66 |
 Luteinising-hormone-releasing hormone plus short-term anti-androgen | 2608 (84) | 92 (87) |  |
 Bicalutamide (150 mg) | 393 (13) | 10 (9) |  |
 Other | 9 (< 1) | 0 (0) |  |
 None | 86 (3) | 4 (4) |  |
Time from start of androgen deprivation therapy to radiotherapy, median (IQR), (weeks) | 16 (14–20) | 17 (14–21) | 0.29 |
Past clinical history of comorbidity, n (%) | |||
 Diabetes | 333 (11) | 9 (8) | 0.57 |
 Hypertension | 1238 (40) | 38 (36) | 0.47 |
 Inflammatory bowel disease | 122 (4) | 2 (2) | 0.42 |
 Symptomatic haemorrhoids | 204 (7) | 5 (5) | 0.58 |
Previous pelvic surgery, n (%) | 244 (8) | 8 (7) | 1.00 |
Previous transurethral resection of the prostate, n (%) | 243 (8) | 16 (15) | 0.01 |
Alpha-blockers or anticholinergic drugs at trial entry, n (%) | 363 (12) | 12 (11) | 1.00 |
Year of entry to the CHHiP trial, n (%) | Â | Â | 0.65 |
 Year 2–3 | 106 (3) | 2 (2) |  |
 Year 4–5 | 258 (8) | 11 (10) |  |
 Year 6–7 | 521 (17) | 17 (16) |  |
 Year 8–9 | 1338 (43) | 41 (39) |  |
 Year 10–11 | 886 (28) | 35 (33) |  |